Four new policies under development may address a variety of lingering regulatory hurdles for foreign drug and device companies in China.
China Market Intelligence
China Halves Retaliatory Tariffs on September 1 List February 6th, 2020
How the US Government is Approaching ICT Supply Chain Security February 5th, 2020
Combatting Coronavirus: Commercial Lessons from SARS February 5th, 2020
Corporate Social Credit is Still a Work in Progress February 5th, 2020
Grappling with Wuhan Coronavirus: Impacts on USCBC Members January 30th, 2020